全文获取类型
收费全文 | 1015篇 |
免费 | 182篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 25篇 |
妇产科学 | 8篇 |
基础医学 | 12篇 |
口腔科学 | 7篇 |
临床医学 | 51篇 |
内科学 | 52篇 |
皮肤病学 | 3篇 |
神经病学 | 9篇 |
特种医学 | 14篇 |
外国民族医学 | 4篇 |
外科学 | 31篇 |
综合类 | 45篇 |
预防医学 | 4篇 |
眼科学 | 370篇 |
药学 | 135篇 |
中国医学 | 3篇 |
肿瘤学 | 440篇 |
出版年
2024年 | 4篇 |
2023年 | 18篇 |
2022年 | 32篇 |
2021年 | 56篇 |
2020年 | 40篇 |
2019年 | 39篇 |
2018年 | 50篇 |
2017年 | 52篇 |
2016年 | 66篇 |
2015年 | 92篇 |
2014年 | 117篇 |
2013年 | 256篇 |
2012年 | 80篇 |
2011年 | 77篇 |
2010年 | 88篇 |
2009年 | 69篇 |
2008年 | 53篇 |
2007年 | 23篇 |
2006年 | 7篇 |
2005年 | 5篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 1篇 |
排序方式: 共有1228条查询结果,搜索用时 15 毫秒
991.
992.
为了评价贝伐单抗联合白蛋白结合型紫杉醇治疗晚期难治性三阴性乳腺癌的临床效果,选取经病理学确诊的晚期三阴性乳腺癌患者6例(ER、PR和HER-2均为阴性),既往使用过蒽环、紫杉类、吉西他滨及卡培他滨等药物治疗后进展,接受贝伐单抗联合白蛋白结合型紫杉醇方案治疗,其中贝伐单抗7.5 mg/kg,静脉滴入,d1,3周重复;白蛋白结合型紫杉醇260 mg/m2,静脉滴入,d1,3周重复,不做抗过敏预处理.3例患者接受化疗6个周期,3例4个周期.PR 2例,SD 3例,PD 1倒.毒副反应主要是骨髓抑制和神经毒性,其中Ⅳ度粒细胞减少1例,Ⅲ度粒细胞减少2倒,Ⅱ度粒细胞减少2倒,Ⅰ度粒细胞减少1例;Ⅲ度感觉神经病变2例,Ⅱ度感觉神经病变2例,Ⅰ度感觉神经病变2例;高血压1倒,蛋白尿2例.初步研究结果提示,贝伐单抗联合白蛋白结合型紫杉醇治疗晚期难治性三阴性乳腺癌疗效较好,毒副反应可耐受,值得进一步研究. 相似文献
993.
F Mori T Ishida A Ito F Sato A Masaki H Takino M Ri S Kusumoto H Komatsu R Ueda H Inagaki S Iida 《Blood cancer journal》2012,2(4):e67
We established a mouse model of microenvironment-dependent human lymphoma, and assessed the therapeutic potential of bevacizumab, an antitumor agent acting on the microenvironment. NOD/Shi-scid, IL-2Rγ(null) (NOG) mice were used as recipients of primary tumor cells from a patient with diffuse large B-cell lymphoma (DLBCL), which engraft and proliferate in a microenvironment-dependent manner. The lymphoma cells could be serially transplanted in NOG mice, but could not be maintained in in vitro cultures. Injection of bevacizumab together with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) significantly increased necrosis and decreased vascularization in the tumor, compared with CHOP alone. Levels of human soluble interleukin-2 receptor (sIL2R) in the serum of bevacizumab+CHOP-treated mice (reflecting the DLBCL tumor burden) were significantly lower than in CHOP recipients. Mice receiving bevacizumab monotherapy also showed significant benefit in terms of tumor necrosis and vascularization, as well as decreased serum sIL2R concentrations. The present DLBCL model reflects the human DLBCL in vivo environment more appropriately than current mouse models using established tumor cell lines. This is the first report to evaluate the efficacy of bevacizumab in such a tumor microenvironment-dependent model. Bevacizumab may be a potential treatment strategy for DLBCL patients. 相似文献
994.
Abajo A Boni V Lopez I Gonzalez-Huarriz M Bitarte N Rodriguez J Zarate R Bandres E Garcia-Foncillas J 《British journal of cancer》2012,107(2):287-290
Background:
To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients.Methods:
Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy.Results:
Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, P<0.05) were observed in patients responding to therapy. Baseline levels of these five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (P<0.01). Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (P<0.05).Conclusion:
This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the efficacy of bevacizumab-containing regimen. 相似文献995.
De Bruyne S Van Damme N Smeets P Ferdinande L Ceelen W Mertens J Van de Wiele C Troisi R Libbrecht L Laurent S Geboes K Peeters M 《British journal of cancer》2012,106(12):1926-1933
Background:
The purpose of this study was to assess the role of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and 18F-fluorodeoxyglucose positron emission tomography computed tomography (FDG-PET/CT) for evaluation of response to chemotherapy and bevacizumab and for prediction of progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) with potentially resectable liver lesions.Methods:
A total of 19 mCRC patients were treated with FOLFOX/FOLFIRI and bevacizumab followed by surgery. Dynamic contrast-enhanced magnetic resonance imaging and FDG-PET/CT were performed before treatment and after cycle 5. PET results were quantified by calculating maximum standardised uptake value (SUVmax) whereas area under the enhancement curve (AUC), initial AUC (iAUC) and the endothelial transfer constant (Ktrans) were used to quantify DCE-MRI. Pathological analysis of the resection specimen was performed, including measurement of microvessel density (MVD) and proliferation index.Results:
Both AUC and iAUC were significantly decreased following bevacizumab therapy (median change of 22% (P=0.002) and 40% (P=0.001) for AUC and iAUC, respectively). Progression-free survival benefit was shown for patients with >40% reduction in Ktrans (P=0.019). In the group of radiological responders, the median baseline SUVmax was 3.77 (IQR: 2.88–5.60) compared with 7.20 (IQR: 4.67–8.73) in nonresponders (P=0.021). A higher follow-up SUVmax was correlated with worse PFS (P=0.012). Median MVD was 10.9. Progression-free survival was significantly shorter in patients with an MVD greater than 10, compared with patients with lower MVD (10 months compared with 16 months, P=0.016).Conclusion:
High relative decrease in Ktrans, low follow-up SUVmax and low MVD are favourable prognostic factors for mCRC patients treated with bevacizumab before surgery. 相似文献996.
Background:The poor prognosis of patients with colorectal-cancer liver metastases (CRLM) and the insufficiency of available treatments have raised the need for alternative curative strategies. We aimed to assess the therapeutic potential of TL-118, a new anti-angiogenic drug combination, for CRLM treatment, in a mouse model.Methods:The therapeutic potential of TL-118 was evaluated and compared with B20-4.1.1 (B20; anti-VEGF antibody) and rapamycin in CRLM-bearing mice. Tumour progression and the vascular changes were monitored by MRI. Additionally, mice survival, cell proliferation, apoptosis and vessel density were evaluated.Results:This study demonstrated an unequivocal advantage to TL-118 therapy by significantly prolonging survival (threefold) and reducing metastasis perfusion and vessel density (ninefold). The underlying mechanism for TL-118-treatment success was associated with hepatic perfusion attenuation resulting from reduced nitric-oxide (NO) serum levels as elucidated by using hemodynamic response imaging (HRI, a functional MRI combined with hypercapnia and hyperoxia). Further, systemic hepatic perfusion reduction during the initial treatment phase by adding NO inhibitor has proven to be essential for reaching maximal therapeutic effects for both TL-118 and B20.Conclusion:TL-118 harbours a potential clinical benefit to CLRM patients. Moreover, the reduction of hepatic perfusion at early stages of anti-angiogenic therapies by adding NO inhibitor is crucial for achieving maximal anti-tumour effects. 相似文献
997.
Sabrina C.C. RIBEIRO Francisco S. VARGAS Leila ANTONANGELO Evaldo MARCHI Eduardo H. GENOFRE Milena M.P. ACENCIO Lisete R. TEIXEIRA 《Respirology (Carlton, Vic.)》2009,14(8):1188-1193
Background and objective: Vascular endothelial growth factor (VEGF) is known to increase vascular permeability and promote angiogenesis. It is expressed in most types of pleural effusions. However, the exact role of VEGF in the development of pleural effusions has yet to be determined. The anti-VEGF mAb, bevacizumab, has been used in the treatment of cancer to reduce local angiogenesis and tumour progression. This study describes the acute effects of VEGF blockade on the expression of inflammatory cytokines and pleural fluid accumulation.
Methods: One hundred and twelve New Zealand rabbits received intrapleural injections of either talc or silver nitrate. In each group, half the animals received an intravenous injection of bevacizumab, 30 min before the intrapleural agent was administered. Five animals from each subgroup were sacrificed 1, 2, 3, 4 or 7 days after the procedure. Twelve rabbits were used to evaluate vascular permeability using Evans's blue dye. Pleural fluid volume and cytokines were quantified.
Results: Animals pretreated with anti-VEGF antibody showed significant reductions in pleural fluid volumes after talc or silver nitrate injection. IL-8 levels, vascular permeability and macroscopic pleural adhesion scores were also reduced in the groups that received bevacizumab.
Conclusions: This study showed that bevacizumab interferes in the acute phase of pleural inflammation induced by silver nitrate or talc, reinforcing the role of VEGF as a key mediator in the production of pleural effusions. The results also suggest that bevacizumab should probably be avoided in patients requiring pleurodesis. 相似文献
Methods: One hundred and twelve New Zealand rabbits received intrapleural injections of either talc or silver nitrate. In each group, half the animals received an intravenous injection of bevacizumab, 30 min before the intrapleural agent was administered. Five animals from each subgroup were sacrificed 1, 2, 3, 4 or 7 days after the procedure. Twelve rabbits were used to evaluate vascular permeability using Evans's blue dye. Pleural fluid volume and cytokines were quantified.
Results: Animals pretreated with anti-VEGF antibody showed significant reductions in pleural fluid volumes after talc or silver nitrate injection. IL-8 levels, vascular permeability and macroscopic pleural adhesion scores were also reduced in the groups that received bevacizumab.
Conclusions: This study showed that bevacizumab interferes in the acute phase of pleural inflammation induced by silver nitrate or talc, reinforcing the role of VEGF as a key mediator in the production of pleural effusions. The results also suggest that bevacizumab should probably be avoided in patients requiring pleurodesis. 相似文献
998.
YANG LQ LAN YQ GUO H CHENG LZ FAN JZ CAI X ZHANG LM CHEN RF ZHOU HS 《Acta pharmacologica Sinica》2010,31(12):1625-1634
Aim:
To investigate the ability of drug-loaded N,O-carboxymethyl chitosan (CMCS) hydrogels to modulate wound healing after glaucoma filtration surgery.Methods:
The drug-loaded CMCS hydrogels were in situ synthesized using genipin as the crosslinker in the presence of 5-fluorouracil (5FU) or bevacizumab. Their structures were characterized by FTIR, ultraviolet-visible (UV-vis) spectroscopy and scanning electron microscopy (SEM). In-vitro drug release experiments and in vivo evaluation in rabbits were performed.Results:
The results of FTIR, UV-vis spectroscopy and SEM analyses indicated that 5FU was encapsulated into the CMCS hydrogels that were crosslinked by genipin. The in vitro drug release experiments showed that nearly 100% of 5FU was released from the drug-loaded hydrogels within 8 h, but less than 20% bevacizumab was released after 53 h. The in vivo evaluation in rabbits indicated that the drug-loaded CMCS hydrogels were nontoxic to the cornea and were gradually biodegraded in the eyes. Furthermore, the drug-loaded CMCS hydrogels effectively inhibited conjunctival scarring after glaucoma filtration surgery and controlled postoperative intraocular pressure (IOP).Conclusion:
The drug-loaded CMCS hydrogels provide a great opportunity to increase the therapeutic efficacy of glaucoma filtration surgery. 相似文献999.
Hyperpolarized 13C‐lactate to 13C‐bicarbonate ratio as a biomarker for monitoring the acute response of anti‐vascular endothelial growth factor (anti‐VEGF) treatment
下载免费PDF全文
![点击此处可从《NMR in biomedicine》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jae Mo Park Daniel M. Spielman Sonal Josan Taichang Jang Milton Merchant Ralph E. Hurd Dirk Mayer Lawrence D. Recht 《NMR in biomedicine》2016,29(5):650-659
Hyperpolarized [1‐13C]pyruvate MRS provides a unique imaging opportunity to study the reaction kinetics and enzyme activities of in vivo metabolism because of its favorable imaging characteristics and critical position in the cellular metabolic pathway, where it can either be reduced to lactate (reflecting glycolysis) or converted to acetyl‐coenzyme A and bicarbonate (reflecting oxidative phosphorylation). Cancer tissue metabolism is altered in such a way as to result in a relative preponderance of glycolysis relative to oxidative phosphorylation (i.e. Warburg effect). Although there is a strong theoretical basis for presuming that readjustment of the metabolic balance towards normal could alter tumor growth, a robust noninvasive in vivo tool with which to measure the balance between these two metabolic processes has yet to be developed. Until recently, hyperpolarized 13C‐pyruvate imaging studies had focused solely on [1‐13C]lactate production because of its strong signal. However, without a concomitant measure of pyruvate entry into the mitochondria, the lactate signal provides no information on the balance between the glycolytic and oxidative metabolic pathways. Consistent measurement of 13C‐bicarbonate in cancer tissue, which does provide such information, has proven difficult, however. In this study, we report the reliable measurement of 13C‐bicarbonate production in both the healthy brain and a highly glycolytic experimental glioblastoma model using an optimized 13C MRS imaging protocol. With the capacity to obtain signal in all tumors, we also confirm for the first time that the ratio of 13C‐lactate to 13C‐bicarbonate provides a more robust metric relative to 13C‐lactate for the assessment of the metabolic effects of anti‐angiogenic therapy. Our data suggest a potential application of this ratio as an early biomarker to assess therapeutic effectiveness. Furthermore, although further study is needed, the results suggest that anti‐angiogenic treatment results in a rapid normalization in the relative tissue utilization of glycolytic and oxidative phosphorylation by tumor tissue. Copyright © 2016 John Wiley & Sons, Ltd. 相似文献
1000.
Je Hyung Hwang Kyeong Do Jeong Kyu Ho Chung Jung Hyun Park Jin Choi Won Hyuk Oh 《Ocular immunology and inflammation》2020,28(4):699-702
ABSTRACT